South Dakota HB1099: reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

What the bill says

An Act ENTITLED An Act to reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

From the enrolled text, March 3, 2026:

An Act ENTITLED An Act to reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance. Be it enacted by the Legislature of the State of South Dakota: Section 1. That § 34-20B-14 be AMENDED: 34-20B-14. Any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, their salts, isomers, and salts of isomers, is included in Schedule I, unless specifically excepted, whenever the existence of the salts, isomers, and salts of isomers is possible within the specific chemical (2) Diethyltryptamine (DET); (3) Dimethyltryptamine (DMT); (4) 5-methoxy-N, N-Dimethyltryptamine (5-MeO-DMT); (5) 5-methoxy-3, 4-methylenedioxy amphetamine; (6) 4-bromo-2, 5-dimethoxyamphetamine; (7) 4-methoxyamphetamine; (8) 4-methoxymethamphetamine; (9) 4-methyl-2, 5-dimethoxyamphetamine; (10) Hashish and hash oil; (11) Ibogaine; (12) Lysergic acid diethylamide; (13) Mescaline; (14) N-ethyl-3-piperidyl benzilate; (15) N-methyl-3-piperidyl benzilate; (16) 1-(-(2-thienyl)cyclohexyl) piperidine (TCP); (17) Peyote, except when used as a sacramental in services of the Native American church, in a natural state that is unaltered, except for drying or curing and cutting or slicing; (18) Psilocybin, except the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the United States Food and Drug Administration; (19) Psilocyn; (20) Tetrahydrocannabinol, except that which occurs in industrial hemp as defined in § 38-35-1; in a drug product approved …

Read the full official text

Sponsors

• Tom Pischke (R, 25) · primary sponsor
• Taylor Rehfeldt (R, HD-014) · primary sponsor
• Sydney Davis (R, 17)
• Eric Emery (D, HD-026)
• Timothy Goodwin (R, HD-030)
• Mellissa Heermann (R, HD-007)
• Scott Moore (R, HD-023)
• Erik Muckey (D, HD-015)
• Brian Mulder (R, HD-011)
• Carl Perry (R, 03)
• Nicole Uhre-Balk (D, HD-032)
• Brandon Wipf (R, SD-022)

Latest actions

1. March 10, 2026: Signed by the Governor
2. March 5, 2026: Delivered to the Governor
3. March 4, 2026: Signed by the President
4. March 3, 2026: Signed by the Speaker
5. March 2, 2026: Do Pass
6. February 26, 2026: Remove from Consent Calendar
7. February 25, 2026: Certified uncontested, placed on consent
8. February 25, 2026: Do Pass
9. February 25, 2026: Scheduled for hearing
10. February 10, 2026: First read in Senate and referred to Health and Human Services

Votes

• Do Pass (March 2, 2026): 21 yea, 12 nay, passed
• Do Pass (February 25, 2026): 6 yea, 0 nay, passed
• Do Pass (February 11, 2026): 58 yea, 7 nay, passed
• Do Pass (February 5, 2026): 13 yea, 0 nay, passed

Common questions

What is HB1099?

HB1099 is a bill in the South Dakota Legislature (101st Legislature (2026)): reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

What does HB1099 do?

In its own words: An Act ENTITLED An Act to reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

What is the status of HB1099?

Signed into law as of March 10, 2026. Latest action: Signed by the Governor (March 10, 2026).

Who sponsored HB1099?

Tom Pischke (R, 25), with 11 co-sponsors.

Where is the official record for HB1099?

On the South Dakota Legislature website: https://sdlegislature.gov/Session/Bill/26592